Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole

Seminars in Nuclear Medicine

Volumn 37, Issue 6, 2007, Pages 451-461

  Lee, Sze Ting ^a,b,c   Scott, Andrew M ^a,b,c  

^a AUSTIN HEALTH   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 NITROIMIDAZOL 1(H) YL] N [3 FLUOROPROPYL)ACETAMIDE] F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 [2 NITRO 1(H) IMIDAZOL 1 YL] N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; COPPER 64; DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) COPPER 64; FLUORAZOMYCINARABINOFURANOSIDE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; OXYGEN 15; RUBIDIUM 82; TIRAPAZAMINE; UNCLASSIFIED DRUG;

CANCER MODEL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG DIFFUSION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS;

ANIMALS; BRAIN ISCHEMIA; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FLUORINE RADIOISOTOPES; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MISONIDAZOLE; MYOCARDIAL ISCHEMIA; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STROKE;

EID: 34848893337     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.07.001     Document Type: Review

References (108)

1. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 (2006) 699-757
2. Foo S.S., Abbott D.F., Lawrentschuk N., et al. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 6 (2004) 291-305
3. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
4. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
5. Hockel M., Schlenger K., Hockel S., et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 79 (1998) 365-369
6. Sundfor K., Lyng H., and Rofstad E.K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 78 (1998) 822-827
7. Walenta S., Wetterling M., Lehrke M., et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60 (2000) 916-921
8. Powis G., and Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 3 (2004) 647-654
9. Kerbel R.S. New targets, drugs, and approaches for the treatment of cancer: An overview. Cancer Metastasis Rev 17 (1998) 145-147
10. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
11. Zagzag D., Friedlander D.R., Margolis B., et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 33 (2000) 49-55
12. Hockel M., Schlenger K., Hockel S., et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59 (1999) 4525-4528
13. Dachs G.U., and Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 36 (2000) 1649-1660
14. Reynolds T.Y., Rockwell S., and Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res 56 (1996) 5754-5757
15. Blancher C., and Harris A.L. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target. Cancer Metastasis Rev 17 (1998) 187-194
16. Padhani A.R., Krohn K.A., Lewis J.S., et al. Imaging oxygenation of human tumours. Eur Radiol 17 (2007) 861-872
17. Menon C., and Fraker D.L. Tumor oxygenation status as a prognostic marker. Cancer Lett 221 (2005) 225-235
18. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7 (2001) 987-989
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
20. Wouters B.G., Weppler S.A., Koritzinsky M., et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 38 (2002) 240-257
21. Padera T.P., Stoll B.R., Tooredman J.B., et al. Pathology: cancer cells compress intratumour vessels. Nature 427 (2004) 695
22. Hall E.J. Radiobiology for the Radiologist. (ed 3) (1988), Lippincott, Philadelphia
23. Hockel M., and Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
24. Ciocca D.R., and Calderwood S.K. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10 (2005) 86-103
25. Stone H.B., Brown J.M., Phillips T.L., et al. Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 136 (1993) 422-434
26. Hicks R.J., Dorow D., and Roselt P. PET tracer development-a tale of mice and men. Cancer Imaging 6 (2006) S102-S106
27. Koh W.J., Rasey J.S., Evans M.L., et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22 (1992) 199-212
28. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
29. Rajendran J.G., Wilson D.C., Conrad E.U., et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30 (2003) 695-704
30. Lawrentschuk N., Poon A.M., Foo S.S., et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 96 (2005) 540-546
31. Cherk M.H., Foo S.S., Poon A.M., et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med 47 (2006) 1921-1926
32. Brown J.M., and Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 82 (1980) 171-190
33. Grunbaum Z., Freauff S.J., Krohn K.A., et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 28 (1987) 68-75
34. Fukuda K., Taniguchi H., Koh T., et al. Relationships between oxygen and glucose metabolism in human liver tumours: Positron emission tomography using (15)O and (18)F-deoxyglucose. Nucl Med Commun 25 (2004) 577-583
35. Flockhart I.R., Large P., Troup D., et al. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica 8 (1978) 97-105
36. Tochon-Danguy H.J., Sachinidis J.I., Chan F., et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 29 (2002) 191-197
37. Graham M.M., Peterson L.M., Link J.M., et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 38 (1997) 1631-1636
38. Lim J.L., and Berridge M.S. An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot 44 (1993) 1085-1091
39. Davda S., and Bezabeh T. Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning. Cancer Metastasis Rev 25 (2006) 469-480
40. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14 (1988) 831-838
41. Rofstad E.K., Sundfor K., Lyng H., et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 83 (2000) 354-359
42. Kallinowski F., Zander R., Hoeckel M., et al. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys 19 (1990) 953-961
43. Vaupel P., Schlenger K., Knoop C., et al. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51 (1991) 3316-3322
44. Shelton M.E., Dence C.S., Hwang D.R., et al. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium. J Nucl Med 30 (1989) 351-358
45. Cater D.B., and Silver I.A. Quantitative measurements of oxygen tension in normal tissues and in the tumours of patients before and after radiotherapy. Acta Radiol 53 (1960) 233-256
46. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48 (1998) 149-156
47. Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest Suppl 106 (1968) 145-157
48. Knocke T.H., Weitmann H.D., Feldmann H.J., et al. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53 (1999) 99-104
49. Hockel M., Knoop C., Schlenger K., et al. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 345 (1994) 445-450
50. Lyng H., Sundfor K., and Rofstad E.K. Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiother Oncol 44 (1997) 163-169
51. Doll C.M., Milosevic M., Pintilie M., et al. Estimating hypoxic status in human tumors: A simulation using Eppendorf oxygen probe data in cervical cancer patients. Int J Radiat Oncol Biol Phys 55 (2003) 1239-1246
52. Hockel M., Schlenger K., Mitze M., et al. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6 (1996) 3-9
53. Nordsmark M., Loncaster J., Chou S.C., et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 49 (2001) 581-586
54. Lartigau E., Randrianarivelo H., Avril M.F., et al. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res 7 (1997) 400-406
55. Nordsmark M., Hoyer M., Keller J., et al. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 35 (1996) 701-708
56. Bentzen L., Keiding S., Nordsmark M., et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67 (2003) 339-344
57. Brizel D.M., Rosner G.L., Harrelson J., et al. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30 (1994) 635-642
58. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
59. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
60. Stadler P., Becker A., Feldmann H.J., et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44 (1999) 749-754
61. Eschwege F., Bourhis J., Girinski T., et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: A review of the Institute Gustave Roussy experience. Int J Radiat Oncol Biol Phys 39 (1997) 849-853
62. Lartigau E., Le Ridant A.M., Lambin P., et al. Oxygenation of head and neck tumors. Cancer 71 (1993) 2319-2325
63. Becker A., Hansgen G., Bloching M., et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42 (1998) 35-41
64. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 (1999) 113-117
65. Eschmann S.M., Paulsen F., Reimold M., et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46 (2005) 253-260
66. Gagel B., Reinartz P., Dimartino E., et al. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 180 (2004) 616-622
67. Zimny M., Gagel B., Dimartino E., et al. FDG-a marker of tumour hypoxia?. A comparison with [(18)F]fluoromisonidazole and pO (2)-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33 (2006) 1426-1431
68. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58 (1998) 1408-1416
69. Gatenby R.A., Coia L.R., Richter M.P., et al. Oxygen tension in human tumors: In vivo mapping using CT-guided probes. Radiology 156 (1985) 211-214
70. Rasey J.S., Nelson N.J., Chin L., et al. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 122 (1990) 301-308
71. Valk P.E., Mathis C.A., Prados M.D., et al. Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33 (1992) 2133-2137
72. Bruehlmeier M., Roelcke U., Schubiger P.A., et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 45 (2004) 1851-1859
73. Cher L.M., Murone C., Lawrentschuk N., et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47 (2006) 410-418
74. Rajendran J.G., Schwartz D.L., O'Sullivan J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12 (2006) 5435-5441
75. Thorwarth D., Eschmann S.M., Holzner F., et al. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80 (2006) 151-156
76. Hicks R.J., Rischin D., Fisher R., et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32 (2005) 1384-1391
77. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 535-542
78. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
79. Gagel B., Reinartz P., Demirel C., et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: A feasibility study. BMC Cancer 6 (2006) 51
80. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33 (1995) 391-398
81. Read S.J., Hirano T., Abbott D.F., et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology 51 (1998) 1617-1621
82. Read S.J., Hirano T., Abbott D.F., et al. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 48 (2000) 228-235
83. Markus R., Reutens D.C., Kazui S., et al. Hypoxic tissue in ischaemic stroke: Persistence and clinical consequences of spontaneous survival. Brain 127 (2004) 1427-1436
84. Markus R., Donnan G., Kazui S., et al. Penumbral topography in human stroke: Methodology and validation of the 'Penumbragram'. Neuroimage 21 (2004) 1252-1259
85. Markus R., Donnan G.A., Kazui S., et al. Statistical parametric mapping of hypoxic tissue identified by [(18)F]fluoromisonidazole and positron emission tomography following acute ischemic stroke. Neuroimage 16 (2002) 425-433
86. Hirano T., Read S.J., Abbott D.F., et al. No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage. Neurology 53 (1999) 2179-2182
87. Caldwell J.H., Revenaugh J.R., Martin G.V., et al. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 36 (1995) 1633-1638
88. Martin G.V., Caldwell J.H., Graham M.M., et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 33 (1992) 2202-2208
89. Hotchkiss R.S., Rust R.S., Dence C.S., et al. Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole. Am J Physiol 261 (1991) R965-R972
90. Liu R.S., Chu L.S., Yen S.H., et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med 23 (1996) 1384-1387
91. Sorger D., Patt M., Kumar P., et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30 (2003) 317-326
92. Piert M., Machulla H.J., Picchio M., et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46 (2005) 106-113
93. Gronroos T., Bentzen L., Marjamaki P., et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 513-520
94. Solomon B., Binns D., Roselt P., et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 4 (2005) 1417-1422
95. Fujibayashi Y., Taniuchi H., Yonekura Y., et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38 (1997) 1155-1160
96. O'Donoghue J.A., Zanzonico P., Pugachev A., et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
97. Laforest R., Dehdashti F., Lewis J.S., et al. Dosimetry of 60/61/62/64Cu-ATSM: A hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging 32 (2005) 764-770
98. Lewis J.S., McCarthy D.W., McCarthy T.J., et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40 (1999) 177-183
99. Obata A., Yoshimoto M., Kasamatsu S., et al. Intra-tumoral distribution of (64)Cu-ATSM: A comparison study with FDG. Nucl Med Biol 30 (2003) 529-534
100. Yuan H., Schroeder T., Bowsher J.E., et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47 (2006) 989-998
101. Gronroos T., Eskola O., Lehtio K., et al. Pharmacokinetics of [18F]FETNIM: A potential marker for PET. J Nucl Med 42 (2001) 1397-1404
102. Lehtio K., Oikonen V., Gronroos T., et al. Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med 42 (2001) 1643-1652
103. Lehtio K., Oikonen V., Nyman S., et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 30 (2003) 101-108
104. Tolvanen T., Lehtio K., Kulmala J., et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 43 (2002) 1674-1680
105. Evans S.M., Kachur A.V., Shiue C.Y., et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41 (2000) 327-336
106. Kachur A.V., Dolbier Jr. W.R., Evans S.M., et al. Synthesis of new hypoxia markers EF1 and [18F]-EF1. Appl Radiat Isot 51 (1999) 643-650
107. Dolbier Jr. W.R., Li A.R., Koch C.J., et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54 (2001) 73-80
108. Ziemer L.S., Evans S.M., Kachur A.V., et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 30 (2003) 259-266